3,123 reports of this reaction
4.2% of all NICOTINE reports
#3 most reported adverse reaction
APPLICATION SITE ERYTHEMA is the #3 most commonly reported adverse reaction for NICOTINE, manufactured by Haleon US Holdings LLC. There are 3,123 FDA adverse event reports linking NICOTINE to APPLICATION SITE ERYTHEMA. This represents approximately 4.2% of all 74,737 adverse event reports for this drug.
NICOTINE has an overall safety score of 78 out of 100. Patients taking NICOTINE who experience application site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE ERYTHEMA is moderately reported among NICOTINE users, representing a notable but not dominant share of adverse events.
In addition to application site erythema, the following adverse reactions have been reported for NICOTINE:
The following drugs have also been linked to application site erythema in FDA adverse event reports:
APPLICATION SITE ERYTHEMA has been reported as an adverse event in 3,123 FDA reports for NICOTINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE ERYTHEMA accounts for approximately 4.2% of all adverse event reports for NICOTINE, making it one of the most commonly reported side effect.
If you experience application site erythema while taking NICOTINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.